Abstract：
To compare the rate of retinal atrophy over time in patients with relapsing-remitting multiple sclerosis (RRMS) treated with various disease-modifying therapies (DMT).
Patients with RRMS on various DMT and those observed without treatment were prospectively enrolled into the study between September 2015 and June 2018. All subjects with follow-up of 1-4 years were included and categorized into groups as \"no drug\", \"low efficacy drug\", \"high efficacy drug\", or \"dimethyl fumarate\" (DMF), based on treatment modality used for the longest duration of their follow-up. Ocular coherence tomography (OCT) was used to measure peripapillary retinal nerve fiber layer thickness (RNFL) and ganglion cell/inner plexiform layer (GC-IPL) thickness at baseline and every 6 months. A linear mixed effects regression model was performed to compare rates of retinal atrophy across treatment groups.
Out of 67 participants who met inclusion criteria (mean age = 37; 76% female), 13 were untreated, 12 on low efficacy therapy, 18 on DMF, and 24 on high efficacy therapy. History of optic neuritis was associated with lower baseline GC-IPL thickness (p = 0.003). Higher baseline GC-IPL thickness was associated with increased rate of GC-IPL thinning (p = 0.009). Age, disease duration, and ethnicity were not predictors of baseline RNFL or GC-IPL thickness, or rate of atrophy of these layers.
There were no differences in rate of GC-IPL atrophy between patients with RRMS on different treatments in this cohort. Age, disease duration, and ethnicity also did not predict retinal atrophy. History of ON was associated with reduced GC-IPL thickness at baseline, consistent with previous research. Rate of GC-IPL thinning was higher for subjects with higher baseline GC-IPL thickness, suggesting a plateau effect.
Patients with RRMS on various DMT and those observed without treatment were prospectively enrolled into the study between September 2015 and June 2018. All subjects with follow-up of 1-4 years were included and categorized into groups as \"no drug\", \"low efficacy drug\", \"high efficacy drug\", or \"dimethyl fumarate\" (DMF), based on treatment modality used for the longest duration of their follow-up. Ocular coherence tomography (OCT) was used to measure peripapillary retinal nerve fiber layer thickness (RNFL) and ganglion cell/inner plexiform layer (GC-IPL) thickness at baseline and every 6 months. A linear mixed effects regression model was performed to compare rates of retinal atrophy across treatment groups.
Out of 67 participants who met inclusion criteria (mean age = 37; 76% female), 13 were untreated, 12 on low efficacy therapy, 18 on DMF, and 24 on high efficacy therapy. History of optic neuritis was associated with lower baseline GC-IPL thickness (p = 0.003). Higher baseline GC-IPL thickness was associated with increased rate of GC-IPL thinning (p = 0.009). Age, disease duration, and ethnicity were not predictors of baseline RNFL or GC-IPL thickness, or rate of atrophy of these layers.
There were no differences in rate of GC-IPL atrophy between patients with RRMS on different treatments in this cohort. Age, disease duration, and ethnicity also did not predict retinal atrophy. History of ON was associated with reduced GC-IPL thickness at baseline, consistent with previous research. Rate of GC-IPL thinning was higher for subjects with higher baseline GC-IPL thickness, suggesting a plateau effect.
摘要：
背景：比较使用各种疾病改善疗法（DMT）治疗的复发缓解型多发性硬化症（RRMS）患者随时间的视网膜萎缩率。
方法：在2015年9月至2018年6月期间，前瞻性招募了接受各种DMT治疗的RRMS患者和未接受治疗的患者。纳入所有随访1-4年的受试者，并将其分为“无药物”组，“低效药物”，“高效药物”，或“富马酸二甲酯”(DMF)，根据随访时间最长的治疗方式。使用眼部相干断层扫描（OCT）测量基线时和每6个月的视网膜周围神经纤维层厚度（RNFL）和神经节细胞/内网状层（GC-IPL）厚度。进行线性混合效应回归模型以比较各治疗组的视网膜萎缩率。
结果：在符合纳入标准的67名参与者中（平均年龄=37岁；76%为女性），13人未经处理，12关于低疗效治疗，18在DMF上，和24在高效治疗上。视神经炎病史与基线GC-IPL厚度较低相关(p=0.003)。较高的基线GC-IPL厚度与GC-IPL变薄速率增加相关(p=0.009)。年龄,疾病持续时间,和种族不是基线RNFL或GC-IPL厚度的预测因子，或这些层的萎缩率。
结论：本队列中不同治疗方法的RRMS患者之间GC-IPL萎缩率无差异。年龄,疾病持续时间,种族也不能预测视网膜萎缩。ON的历史与基线时GC-IPL厚度降低有关，与以往的研究一致。基线GC-IPL厚度较高的受试者的GC-IPL变薄率较高，表明了高原效应.
方法：在2015年9月至2018年6月期间，前瞻性招募了接受各种DMT治疗的RRMS患者和未接受治疗的患者。
结果：在符合纳入标准的67名参与者中（平均年龄=37岁；76%为女性），
结论：本队列中不同治疗方法的RRMS患者之间GC-IPL萎缩率无差异。
